917396-45-3

Basic information

• Product Name: (4-(ethylsulfonyl)phenyl)methanol
• Synonyms: (4-(ethylsulfonyl)phenyl)methanol
• CAS NO: 917396-45-3
• Molecular Formula: C₉H₁₂O₃S
• Molecular Weight: 200.25478
• Mol File: 917396-45-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-(ethylsulfonyl)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(ethylsulfonyl)phenyl)methanol(917396-45-3)
• EPA Substance Registry System: (4-(ethylsulfonyl)phenyl)methanol(917396-45-3)

Safety Data

• Hazardous Substances Data: 917396-45-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-(ethylsulfonyl)phenyl)methanol is used as an intermediate in the synthesis of pharmaceuticals for its unique properties and reactivity in organic synthesis.
Used in Agrochemical Industry:
(4-(ethylsulfonyl)phenyl)methanol is used as an intermediate in the synthesis of agrochemicals for its unique properties and reactivity in organic synthesis.
Used in Specialty Chemicals Production:
(4-(ethylsulfonyl)phenyl)methanol is used as a building block in the production of specialty chemicals and materials for various industrial applications due to its unique properties and reactivity in organic synthesis.

Upstream product

• 84211-94-9 4-(ethylthio)benzaldehyde 
• 459-57-4 4-fluorobenzaldehyde 
• 50899-03-1 4-(ethanesulfonyl)benzaldehyde 
• 21571-66-4 4-(ethylsulfonyl)benzoic acid 

Downstream Products

• 917396-46-4 1-(chloromethyl)-4-(ethylsulfonyl)benzene 
• 90561-19-6 1-(bromomethyl)-4-(ethylsulfonyl)benzene 

Relevant articles and documents

PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS

Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroidreceptor, particularly androgen receptor,dependent diseases and conditions, such asprostate cancer.

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compou

COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY

Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.

NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Triazolopyridine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.